CADTH Health Technology Review

Chlorhexidine Gluconate for Skin Preparation During Catheter Insertion and Surgical Procedures

Rapid Review

Authors: Kylie Tingley, Mê-Linh Lê

Abbreviations

CHG

chlorhexidine gluconate

HAI

health care–associated infection

ICU

intensive care unit

MDRO

multi-drug–resistant organism

MRSA

methicillin-resistant Staphylococcus aureus

SR

systematic review

RCT

randomized controlled trial

VRE

vancomycin-resistant enterococci

Key Messages

Context and Policy Issues

Health care–associated infections (HAIs), many of which are preventable, represent a large proportion of adverse events experienced by those receiving care in the Canadian health care system. It is estimated that the prevalence of patients in Canada with at least 1 HAI was 7.9% in 2017 and that device-associated infections accounted for 35.6% of all HAIs.1 It is also estimated that 9% of HAIs observed in Canadian hospitals were caused by an antimicrobial-resistant organism such as, for example, methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococci (VRE).1 The management of HAIs in Canada incurs substantial costs to the health care system, contributes to lengthier hospital stays, and places an added burden on an already strained system.2 For example, the Canadian Institute for Health Information estimated that HAIs were associated with a cost of $281 million dollars in 2014–2015.3 Infection prevention measures, such as skin cleaning before a procedure or at regular intervals for venous access sites, have been implemented as a strategy to reduce the prevalence HAIs.

Chlorhexidine gluconate (CHG) is an antiseptic that can be used for skin cleaning and has been shown to be effective against a wide range of organisms, including some antimicrobial-resistant organisms.4 CHG is manufactured in several different formulations and concentrations, such as hand scrubs, concentrated solutions that can be diluted with water or alcohol, and CHG-impregnated wipes or sponges.5 While disposable CHG wipes may be convenient, offer good contact with the skin, and uniformity in skin coverage, there are remaining questions regarding their clinical effectiveness compared to other CHG products and skin cleaning techniques.

The objective of this report is to summarize the evidence regarding the clinical effectiveness of CHG wipes for infection prevention in patients being prepped for urinary catheter insertion and in patients who are preoperative and/or in critical care settings.

Research Questions

  1. What is the clinical effectiveness of chlorhexidine gluconate wipes for infection prevention in patients being prepped for a urinary catheter insertion?

  2. What is the clinical effectiveness of chlorhexidine gluconate wipes for infection prevention in patients who are preoperative and/or admitted to the critical care setting?

Methods

Literature Search Methods

A limited literature search was conducted by an information specialist on key resources including MEDLINE, the Cochrane Database of Systematic Reviews, the Cumulative Index to Nursing and Allied Health Literature (CINAHL), the international HTA database, the websites of Canadian and major international health technology agencies, as well as a focused internet search. The search strategy consisted of both controlled vocabulary, such as the National Library of Medicine’s MeSH (Medical Subject Headings), and keywords. The main search concepts were chlorhexidine and wipes/skin preparation, and urinary catheters or surgical intensive care unit or critical care settings. Search filters were applied to limit to health technology assessments, systematic reviews (SRs), meta-analyses, network meta-analyses, all types of clinical trials, and observational studies. The initial search was limited to English-language documents published between January 1, 2016 and June 22, 2021.

Selection Criteria and Methods

One reviewer screened citations and selected studies. In the first level of screening, titles and abstracts were reviewed and potentially relevant articles were retrieved and assessed for inclusion. The final selection of full-text articles was based on the inclusion criteria presented in Table 1.

Table 1: Selection Criteria

Criteria

Description

Population

Q1: Patients in the acute care or community (e.g., LTC or home) setting being prepped for a urinary catheter insertion

Q2: Preoperative patients and/or patients in the critical care setting

Intervention

Q1: CHG wipes or prep sticks (e.g., 0.1% to 0.5% CHG formulation)

Q2: CHG wipes (e.g., 2% CHG) or CHG sponge (e.g., 4% CHG)

Comparator

Q1: PVP wipes, saline cleansing/wipes

Q2: Soap and water (e.g., using soap cleanser)

Outcomes

Q1: Clinical effectiveness: infection rate (i.e., catheter-associated urinary tract infections, hospital-acquired urinary tract infections); adverse events (e.g., skin irritation, chlorhexidine resistance)

Q2: Clinical effectiveness: infection rate (i.e., surgical site infections, level of antibiotic-resistant organisms (e.g., MRSA) or drug-resistant microbes; adverse events (e.g., skin irritation, chlorhexidine resistance)

Study designs

HTA, systematic reviews, randomized controlled trials, non-randomized studies

CHG = chlorhexidine gluconate; HTA = health technology assessment; LTC = long-term care; MRSA = methicillin-resistant Staphylococcus aureus; PVP = polyvinylpyrrolidone.

Exclusion Criteria

Articles were excluded if they did not meet the selection criteria outlined in Table 1, they were duplicate publications, or were published before 2016. SRs in which all relevant studies were captured in other more recent or more comprehensive SRs were excluded. Primary studies retrieved by the search were excluded if they were captured in 1 or more included SRs.

Critical Appraisal of Individual Studies

The included publications were critically appraised by 1 reviewer using the following tools as a guide: A MeaSurement Tool to Assess systematic Reviews 2 (AMSTAR 2)6 for SRs and the Downs and Black checklist7 for randomized and non-randomized studies. Summary scores were not calculated for the included studies; rather, the strengths and limitations of each included publication were described narratively.

Summary of Evidence

Quantity of Research Available

A total of 363 citations were identified in the literature search. Following the screening of titles and abstracts, 319 citations were excluded and 44 potentially relevant reports from the electronic search were retrieved for full-text review. Two potentially relevant publications were retrieved from the grey literature search for full-text review. Of these potentially relevant articles, 39 publications were excluded for various reasons and 7 publications met the inclusion criteria and were included in this report. These comprised 2 SRs,8,9 1 randomized controlled trial (RCT),10 and 4 non-randomized studies.11-14 Appendix 1 presents the PRISMA15 flow chart of the study selection.

Additional references of potential interest are provided in Appendix 6.

Summary of Study Characteristics

Two SRs,8,9 1 RCT,10 and 4 non-randomized studies11-14 were identified and included in this report. Additional details regarding the characteristics of included publications are provided in Appendix 2.

The 2 included SRs8,9 had broader inclusion criteria than the current review. Specifically, both SRs8,9 included studies examining the effects of CHG bathing (not specific to CHG wipes) on the incidence of hospital-acquired infections compared to usual care or non-CHG bathing. In addition, the SR conducted by Musuuza et al. (2019)9 included any adult health care setting, whereas the SR conducted by Huang et al. (2016)8 focused specifically on adult intensive care unit (ICU) settings. Only the characteristics and results of the subset of relevant studies will be described in this report.

Study Design

One SR included RCTs, cluster randomized trials, and non-randomized studies published from inception to January 4, 2019.9 The second SR also included RCTs and non-randomized studies (interrupted time series studies and before-and-after studies), and included studies from inception to December 31, 2014.8 Of the 26 studies (8 RCTs and 18 non-randomized studies) included in the SR by Musuuza et al.,9 only primary studies that compared bathing with CHG wipes versus soap and water in ICU settings were relevant to this report (i.e., 2 RCTs and 7 non-randomized studies). Of the 15 studies included in the SR by Huang et al.,8 only primary studies that compared bathing with CHG wipes versus soap and water in ICU settings were relevant to this report (i.e., 1 RCT and 6 non-randomized studies). The overlap of primary studies relevant to the current review and included in both SRs is provided in Appendix 5.

One single-centre RCT published in 2016 by Kapadia et al.10 was included.

The remaining 4 studies were non-randomized designs. The study by Tien et al. was a prospective, cluster, quasi-experimental controlled before-and-after study.14 The study by Kengen et al. was a retrospective, single-centre, sequential period, interrupted time series design in which the outcomes were measured monthly over an 11-month control period and then again during an 11-month intervention period.12 Garrido-Benedicto et al. (2017) and Ruiz et al. (2017) both conducted prospective, single-centre before-and-after studies.11,13

Country of Origin

One of the included SRs was conducted by a research group in the US9 and the other was conducted by a research group in China.8 Among the primary clinical studies included, 2 were conducted in Spain11,13 and the remaining 3 were conducted in Taiwan,14 Australia,12 and the US.10

Patient Population

One SR had broader inclusion criteria than the inclusion criteria for this review. The SR by Musuuza et al. (2019) included studies on hospitalized adults from the ICU, general hospital units, and long-term acute care setting, which were eligible for inclusion.9

Kapadia et al. recruited adult patients from a single centre undergoing a joint arthroplasty, specifically a total knee or hip arthroplasty.10

As previously mentioned, Kapadia et al. recruited patients pre-surgery;10 the remaining 6 studies focused on adult patients admitted to critical care settings. The study settings for these publications included medical and/or surgical ICUs,8,9,11-13 general ICUs,14 coronary care units,9,14 cardiac ICUs,9,14 stroke units,14 emergency care units,14 trauma ICUs,8,9 and bone marrow transplant units.9

Interventions and Comparators

The SRs conducted by Musuuza et al. (2019)9 and Huang et al. (2016)8 had broader inclusion criteria for interventions and comparators than the current report. Musuuza et al.9 included studies with any CHG bathing intervention (e.g., CHG wipes, diluted CHG solution) compared with non-CHG bathing (not otherwise described). All 9 primary studies identified in the SR by Musuuza et al. (2019)9 that met eligibility criteria for this report compared 2% CHG-impregnated wipe bathing with soap and water bathing. Huang et al. (2016)8 also included studies comparing daily CHG bathing, regardless of formulation, compared with daily soap and water or routine care bathing. All 7 primary studies identified in the SR by Huang et al. (2016)8 that met eligibility criteria for this report compared daily 2% CHG-impregnated wipes with daily soap and water bathing.

Four of the included primary studies evaluated bathing with 2% CHG-impregnated washcloths.10,12-14 All 2% CHG wipes were commercially prepared by either Clinell Chlorhexidine Wash Cloths, Clinell (GAMA Healthcare) London, UK;13 Teleflex Medical Australia, Sydney, New South Wales;12 TBF Biotech, Taipei, Taiwan;14 or Sage Products LLC, Illinois, US.10 The study by Garrido-Benedicto et al. evaluated 4% CHG-impregnated sponge (Dispomedic sponge C, CV Médica, Tarragona, Spain).11 CHG bathing of patients in the ICU was performed daily as the intervention (or every second day) in 4 primary studies.11-14 Kapadia et al. instructed study participants to use 6 2% CHG-impregnated cloths the night and morning before their surgery.10 In all 5 of the included primary studies, soap and water was the comparator.10-14

Outcomes

Kapadia et al.10 evaluated the incidence of deep periprosthetic infection as their primary outcome.10 The remaining 6 studies included in this review evaluated a range of outcomes related to the clinical effectiveness of CHG bathing, including the incidence or prevalence rates of hospital-acquired bloodstream infections;9 catheter-related bloodstream infections8 and catheter-associated urinary tract infections;8 ventilator-associated pneumonia;8 the acquisition of MRSA, VRE, or other multi-drug–resistant organism (MDRO);8,11-14 health care facility–onset Clostridium difficile infection cases between 48 hours after ICU admission through to 48 hours after ICU discharge;12 and blood culture contamination.11 Five studies reported on adverse events.8,10,11,13,14

Summary of Critical Appraisal

Systematic Reviews

Strengths of both SRs8,9 were related to publication or registration of methods a priori, the comprehensive literature search, the use of appropriate risk of bias assessments, their adequate explanations for any heterogeneity observed, and discussion of publication bias. Defining the protocol for an SR a priori coupled with comprehensive reporting reduces the risk of bias, particularly reporting bias, and increases the transparency and reproducibility of the review. Comprehensive literature searching reduces the risk of missing potentially relevant studies and in turn, provides a more complete picture of the literature at the time. In addition, conducting adequate risk of bias assessments and assessing possible explanations for observed heterogeneity strengthens the validity of the results.

Regarding limitations, in both SRs, details were missing as to which studies were excluded from the review and the authors did not report on the funding sources for the included studies. Without details for excluded studies, no conclusions can be drawn about their potential impact. It is important to report the funding sources for included studies so that the potential for industry bias of the primary studies can be adequately considered. Given that the majority of primary studies included in each SR were non-randomized, it may limit the certainty of the findings from the review; however, authors of both SRs did report that most of the included non-randomized studies were of high quality according to their risk of bias assessments. In addition, some aspects of the SR conducted by Huang et al.8 were not clear; for example, the authors did not report whether study selection was done in duplicate or not, which could have led to errors in study selection. There were also some inconsistencies noted in the reporting of primary study characteristics in the SR conducted by Huang et al.,8 contributing to uncertainty about reporting in the remainder of the article. Huang et al.8 also did not report on the funding source of the review or the potential conflicts of interest of the authors, which increases the risk of industry bias.

Randomized Controlled Trial

One RCT10 was included in this report. The reporting of this study’s objective, inclusion and exclusion criteria, intervention, comparator, and main outcome were all well-described, which is a strength when it comes to transparency and reproducibility of results. Study participants were randomized using a computer-generated algorithm; thus, balancing potential unmeasured confounding factors and reducing the risk of selection bias. Authors report in the discussion that the study was double-blinded; however, there were no details provided in the methods section about the blinding procedures. Another limitation of this study is the lack of description for participants who were randomized but did not complete the study. Kapadia and colleagues10 reported that 35 participants (11.4%) in the intervention group and 8 (2.9%) in the control group did not complete the study. This unequal dropout between study arms increases the risk of attrition bias and potentially creates imbalances among participant characteristics, and it is unclear what contributed to the higher dropout rate in the intervention group. Kapadia et al.10 also used a per-protocol analysis rather than an intention-to-treat analysis, which may have affected the study findings. An intention-to-treat analysis more accurately reflects real-world clinical practice, where dropout and noncompliance would happen, and keeps the statistical power unchanged. Another potential limitation is possible compliance issues among the intervention group as acknowledged by the study authors in their discussion; however, no data were provided to assess study participant compliance with the assigned intervention.

Non-Randomized Studies

There were 4 non-randomized studies included in this review; 3 before-and-after studies,11,13,14 and 1 interrupted times series study.12 These 4 studies provided good descriptions of their objectives, inclusion and exclusion criteria, intervention, comparators, and main outcomes. Comprehensive reporting is a strength, as it improves the transparency and reproducibility of results. In addition, the statistical analyses that were conducted for the main outcome in each of the 4 studies were appropriate, which increases the internal validity of the study.

There were several limitations associated the 4 non-randomized studies and the results from these studies should be interpreted with caution. Without randomization, there is a risk that the association between an intervention and an outcome is due to unmeasured confounding factors (e.g., variation in staff practices and compliance or patient characteristics during the study periods), which threatens the internal validity of the study. Before-and-after studies are also subject to history bias because data are collected from 2 different time periods. As well, before-and-after studies are at risk of the Hawthorne effect, whereby behaviour changes when subjects know they are being observed. For example, it is unknown whether the vigilance of the ICU care staff regarding bathing techniques used on patients differed after the implementation of the CHG intervention compared to the pre-intervention period. Interrupted time series design, such as that used by Kengen et al.,12 are also subject to problems with confounders that vary over time, as their design is similar to that of a before-and-after study, but the data collection and analyses may be more robust.

All 4 studies were conducted in settings that would be representative of usual care for those in an ICU; however, 2 studies limited their study populations to those who had been in the ICU for more than 48 hours11 or more than 24 hours.12 While this is likely reflective of the focus on newly acquired HAIs, this may exclude some patients who may still require bathing and who may represent a clinically different group of patients. In addition, Tien et al.14 assigned 4 ICUs with a higher baseline VRE-HAIs incidence to provide 2% CHG bathing on a daily (or every 2 days) basis to all patients in the CHG group, while 4 ICUs with a lower baseline VRE-HAIs incidence were assigned to provide standard care (without 2% CHG bathing) to all patients in the standard care group. This could have led to an overestimate of the intervention effect, as the baseline rate of VRE-HAI was different between the 2 groups.

Additional details regarding the strengths and limitations of included publications are provided in Appendix 3.

Summary of Findings

Appendix 4 presents the main study findings and authors’ conclusions.

Clinical Effectiveness of CHG Wipes for Infection Prevention in Patients Being Prepped for a Urinary Catheter Insertion

No relevant evidence regarding CHG wipes for infection prevention in patients being prepped for a urinary catheter insertion was identified; therefore, no summary can be provided.

Clinical Effectiveness of CHG Wipes for Infection Prevention in Patients Pre-Surgery or Admitted to the Critical Care Setting

Two SRs,8,9 1 RCT,10 and 4 non-randomized studies11-14 were identified and included in this report. The studies included in this review reported results pertaining to rates of surgical site infections,10 health care–associated infections8,9,11-14, blood culture contamination,11 and adverse events.8,10,11,13,14 There was some overlap in the primary studies that were included in the SRs (see Appendix 5); however, as the results of the SRs are presented narratively, the data are only presented once by primary study.

Surgical Site Infections

One primary study was identified with respect to using CHG wipes for infection prevention pre-surgery.10 The results from this RCT demonstrated that using 2% CHG-impregnated cloths the night before and morning of admission significantly reduced the likelihood of deep periprosthetic infections in patients undergoing total joint arthroplasty (hip and knee) when compared to standard soap and water bathing. This result was associated with a wide confidence interval, which suggests some uncertainty in the finding.

Health Care–Associated Bloodstream Infections

Nine primary studies included in the SR by Musuuza et al. (2019)9 that were eligible for this review reported on health care–associated bloodstream infections and there was complete overlap among the eligible primary studies from the Huang et al. (2016)8 SR addressing this outcome; thus, the results from the relevant studies are only reported once. A citation matrix illustrating the degree of overlap is presented in Appendix 5. Of these 9 primary studies, 5 reported an incidence rate ratio that suggested a statistically significant reduction in health care–associated bloodstream infections when comparing bathing with CHG-impregnated wipes versus soap and water bathing, and 4 studies suggested no difference between groups. Together, these data suggest that 2% CHG bathing either reduces or has no difference in the risk of hospital-associated bloodstream infections compared with soap and water bathing.

Catheter-Associated Urinary Tract Infections

Four studies included in the SR by Huang et al. (2016)8 that were eligible for this review reported on catheter-associated urinary tract infections. Of these 4 studies, 1 study reported a risk ratio that suggested a statistically significant reduction in catheter-associated urinary tract infections when comparing bathing with CHG-impregnated wipes versus soap and water bathing, and 3 studies reported no difference between groups. Together, these data suggest that 2% CHG bathing either reduces the risk of catheter-associated urinary tract infections or has no effect compared with soap and water bathing.

Ventilator-Associated Pneumonia

Three studies included in the SR by Huang et al. (2016)8 that were eligible for this review reported on ventilator-associated pneumonia. All 3 studies reported no difference in ventilator-associated pneumonia when comparing bathing with CHG-impregnated wipes versus soap and water bathing.

Acquisition of MRSA, VRE, or Another MDRO

Two studies included in the SR by Huang et al. (2016)8 that were eligible for this review reported on the acquisition of MRSA. Both studies reported no difference in the acquisition of MRSA when comparing bathing with CHG-impregnated wipes versus soap and water bathing.

Among the primary studies included in this report, Tien et al.14 showed that daily bathing with 2% CHG wipes was associated with a lower risk of VRE-HAI after adjusting for the effects of VRE carriage at ICU entry and the length of hospital stay. Conversely, Kengen et al.12 demonstrated no difference in the incidence rates of newly acquired MRSA among ICU patients. Similarly, Ruiz et al.13 reported no reductions in the overall incidence of nosocomial infections or those infections caused by MDROs (i.e., MRSA, VRE, multi-drug–resistant gram-negative organisms, Clostridium difficile) when comparing CHG bathing to soap and water bathing.

Blood Culture Contamination

Two non-randomized studies reported on the incidence of blood culture contamination. Garrido-Benedicto et al.11 reported that the use of 4% CHG-impregnated sponges significantly reduced the incidence of positive blood cultures compared to soap and water bathing. However, Kengen et al.12 reported no difference in the risk of in the blood culture contamination when 2% CHG wipe bathing was compared to soap and water bathing, and their interrupted time series analysis showed no change in the month-to-month trend in the number of positive blood cultures.

Adverse Events

One SR8,9 and 4 primary studies reported on adverse skin reactions.10,11,13,14 Kapadia et al. reported that red wheals occurred in 1 of 275 patients in the CHG intervention group but was resolved with 2 days. Huang et al.8 reported that 1 primary study included in their SR noted that 3 study participants were excluded from the CHG arm of the study because of a rash; however, it was later determined that the rash was not due to CHG bathing. No further details were reported. The remaining 3 studies reported no adverse skin reactions. No other adverse events were reported.

Limitations

The primary limitation of this review is the lack of evidence regarding the clinical effectiveness of CHG wipes for infection prevention among patients being prepped for urinary catheter insertion, as well as for preoperative patients. A single study was identified regarding CHG wipes for infection prevention in patients who were preoperative. Additionally, while the non-randomized studies included in the SRs were assessed by the authors to have a low risk of bias, there were no other high-quality primary studies identified in this report regarding the clinical effectiveness of CHG wipes for infection prevention among patients in critical care settings.

Most of the studies took place at a single site and none of the studies were conducted in Canada. Thus, the generalizability to the Canadian context is unclear.

Conclusions and Implications for Decision- or Policy-Making

This review comprised 2 SRs,8,9 1 RCT,10 and 4 non-randomized studies11-14 evaluating the clinical effectiveness of CHG wipes for infection prevention among patients pre-surgery or in critical care settings. No literature was identified with respect to the clinical effectiveness of CHG wipes for infection prevention among patients being prepped for a urinary catheter insertion.

Based on the evidence summarized, there appears to be a modest association between CHG wipes and reduction in surgical site infections10 when compared to cleansing with soap and water; however, this finding is based on 1 RCT and there is some uncertainty in the finding. The results were mixed for the association of CHG wipes with reduction in health care–associated blood stream infections;8,9,12,14 catheter-associated urinary tract infections;8 acquisition of MRSA, VRE, or another MDRO;12-14 and blood culture contamination11,12 compared to soap and water. In some studies, there was a statistically significant reduction of health care–associated bloodstream infections;9 catheter-related urinary tract infections;8 the acquisition of MRSA, VRE, or another MDRO;8,14 and blood culture contamination11 when CHG wipes were used in critical care settings compared to soap and water. In other studies, however, no differences were observed between intervention groups.8,9,12,13 No difference was observed between bathing with CHG wipes compared to soap and water for the incidence of ventilator-associated pneumonia among patients in the ICU. Thus, we can conclude that, compared to bathing with soap and water, bathing with CHG-impregnated wipes in critical care settings results in either a reduction or no difference in the risk of infection but does not increase the risk of infection. For adverse events, 2 studies8,10 reported mild adverse skin reactions during the CHG bathing period, while 3 other studies11,13,14 reported no adverse events. Bathing with CHG-impregnated wipes appears to be safe.

The limitations of the included literature (e.g., unequal dropout in the RCT, potential for unmeasured confounding in non-randomized studies) should be considered when interpreting the findings of this report. More robust research using well-designed, high-quality studies is required to support the clinical effectiveness and subsequent decision-making regarding the use of CHG-impregnated wipes versus soap and water for infection prevention in pre-surgical and critical care settings.

A previous CADTH report from 2016 that reviewed the clinical and cost-effectiveness evidence regarding CHG wipes for infection prevention in adult patients in acute or critical care settings also identified conflicting evidence regarding the clinical effectiveness of CHG wipes in critical care settings based on the review of 5 publications.16

References

1.Mitchell R, Taylor G, Rudnick W, et al. Trends in health care–associated infections in acute care hospitals in Canada: an analysis of repeated point-prevalence surveys. CMAJ. 2019;191(36):E981-E988. PubMed

2.Tessier L, Guilcher SJT, Bai YQ, Ng R, Wodchis WP. The impact of hospital harm on length of stay, costs of care and length of person-centred episodes of care: a retrospective cohort study. CMAJ. 2019;191(32):E879-E885. PubMed

3.Measuring patient harm in Canadian hospitals. Ottawa (ON): Canadian Institute for Health Information; 2016: https://secure.cihi.ca/free_products/cihi_cpsi_hospital_harm_en.pdf. Accessed 2021 Jul 18.

4.Lim KS, Kam PC. Chlorhexidine--pharmacology and clinical applications. Anaesth Intensive Care. 2008;36(4):502-512. PubMed

5.Chlorhexidine gluconate (topical): drug information. In: Post TW, ed. UpToDate. Waltham (MA): UpToDate; 2021: https://www.uptodate.com. Accessed 2021 Jun 23.

6.Shea BJ, Reeves BC, Wells G, et al. AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both. BMJ. 2017;358:j4008. PubMed

7.Downs SH, Black N. The feasibility of creating a checklist for the assessment of the methodological quality both of randomised and non-randomised studies of health care interventions. J Epidemiol Community Health. 1998;52(6):377-384. PubMed

8.Huang HP, Chen B, Wang HY, He M. The efficacy of daily chlorhexidine bathing for preventing healthcare-associated infections in adult intensive care units. Korean J Intern Med. 2016;31(6):1159-1170. PubMed

9.Musuuza JS, Guru PK, O'Horo JC, et al. The impact of chlorhexidine bathing on hospital-acquired bloodstream infections: a systematic review and meta-analysis. BMC Infect Dis. 2019;19(1):416. PubMed

10.Kapadia BH, Elmallah RK, Mont MA. A randomized, clinical trial of preadmission chlorhexidine skin preparation for lower extremity total joint arthroplasty. J Arthroplasty. 2016;31(12):2856-2861. PubMed

11.Garrido-Benedicto P, Cueto-Quintana P, Farre-Termens E, Marine-Cabre M, Riba-Reig J, Molina-Chueca R. Effect of daily cleaning with chlorhexidine on the incidence of contamination of blood cultures in the critical patient. Enferm Intensiva. 2017;28(3):97-104. PubMed

12.Kengen R, Thoonen E, Daveson K, et al. Chlorhexidine washing in intensive care does not reduce bloodstream infections, blood culture contamination and drug-resistant microorganism acquisition: an interrupted time series analysis. Crit Care Resusc. 2018;20(3):231-240. PubMed

13.Ruiz J, Ramirez P, Villarreal E, et al. Daily bathing strategies and cross-transmission of multidrug-resistant organisms: Impact of chlorhexidine-impregnated wipes in a multidrug-resistant gram-negative bacteria endemic intensive care unit. Am J Infect Control. 2017;45(10):1069-1073. PubMed

14.Tien KL, Wang JT, Sheng WH, et al. Chlorhexidine bathing to prevent healthcare-associated vancomycin-resistant Enterococcus infections: A cluster quasi-experimental controlled study at intensive care units. J Formos Med Assoc. 2021;120(3):1014-1021. PubMed

15.Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. J Clin Epidemiol. 2009;62(10):e1-e34. PubMed

16.Chlorhexidine gluconate wipes for infection prevention in acute and critical care: a review of clinical effectiveness and cost-effectiveness. Rapid response report: summary with critical appraisal. Ottawa (ON): CADTH; 2016: https://www.cadth.ca/sites/default/files/pdf/htis/apr-2016/RC0769%20Chlorhexidine%20Wipes%20Final.pdf. Accessed 2021 Jul 19.

Appendix 1: Selection of Included Studies

Figure 1: Selection of Included Studies

363 citations were identified, 319 were excluded, while 44 electronic literature and 2 grey literature potentially relevant full-text reports were retrieved for scrutiny. In total, 7 reports are included in the review.

Appendix 2: Characteristics of Included Publications

Note that this appendix has not been copy-edited.

Table 2: Characteristics of Included Systematic Reviews and Meta-Analyses

Study citation, country, funding source

Study designs and numbers of primary studies included

Population characteristics

Intervention and comparator(s)

Relevant clinical outcomes, length of follow-up

Musuuza et al. (2019)9

US

Funding source: Agency for Healthcare Research and Quality [R18HS024039] and the United States Veterans Affairs National Center for Patient Safety Center of Inquiry

All included studies:

  • 8 RCTs or cluster randomized controlled trials

  • 18 quasi-experimental studies

Relevant included studies:

  • 2 RCTs or cluster randomized trials

  • 7 quasi-experimental studies

Eligible populations:

  • hospitalized adults, including ICU, general hospital, and long-term acute care settings

Relevant population:

  • hospitalized adults in ICU

Eligible interventions:

  • CHG bathing

Relevant intervention:

  • bathing with CHG-impregnated wipes

Eligible comparators:

  • non-CHG bathing (not otherwise specified)

Relevant comparator:

  • soap and water bathing

  • incidence of hospital-acquired bloodstream infections

Follow-up: NR

Huang et al. (2016)8

China

Funding source: NR

All included studies:

  • 3 RCTs

  • 12 quasi-experimental studies (all before-and-after studies)

Relevant included studies:

  • 1 RCT or cluster randomized trials

  • 6 quasi-experimental studies

  • Adult patients in ICU

Eligible intervention:

  • daily CHG bathing

Relevant intervention:

  • bathing with CHG-impregnated wipes

Eligible comparators:

  • soap and water or routine care bathing

Relevant comparator:

  • soap and water bathing

  • catheter-related bloodstream infections

  • catheter-associated urinary tract infections

  • ventilator-associated pneumonia

  • acquisition of MRSA and VRE

  • adverse events

Follow-up: NR

CHG = chlorhexidine gluconate; ICU = intensive care unit; MRSA = Methicillin-resistant Staphylococcus aureus; NR = not reported; RCT = randomized controlled trial; VRE = vancomycin-resistant Enterococcus.

Table 3: Characteristics of Included Primary Clinical Studies

Study citation, country, funding source

Study design

Population characteristics

Intervention and comparator(s)

Clinical outcomes, length of follow-up

Randomized Controlled Trials

Kapadia et al. (2016)10

US

Funding source: Sage Products, LLC

Study design: single-centre, prospective, randomized controlled trial

Setting: tertiary care centre

Objective: to compare chlorhexidine cloths to standard-of-care antiseptic bathing in patients before total join arthroplasty to evaluate any differences in periprosthetic infection risk

Adult patients undergoing a joint arthroplasty, specifically a total knee arthroplasty or total hip arthroplasty

Number of patients:

N = 539

Mean (SD) age and % female:

  • 62 (NR) years and 62.1% in control group

  • 61 (NR) years and 64.0% in intervention group

Intervention: 2 packets containing 6 2% CHG-impregnated cloths (Sage Products LLC), along with instructions for use the night before and morning of surgery

N = 272

Comparator: bathing instructions with antibacterial soap and water the night before surgical admission

N = 267

Outcomes:

  • incidence of deep periprosthetic infection (primary)

  • adverse events

Follow-up:

  • patients were followed for 1 year post-operatively

Non-Randomized Studies

Tien et al. (2021)14

Taiwan

Funding source: PBF Biotech (Taipei, Taiwan) provided CHG wipes, otherwise, no funding source reported

Study design: Cluster quasi-experimental controlled before-and-after study

Setting: 8 medical ICU of the National Taiwan University Hospital (80 beds in total)

Objective: to assess the effect of CHG bathing to prevent VRE-HAIs at ICUs

Adult patients in ICU

Number of patients:

N = 4,800 in total

Median age (IQR) and % female:

Intervention:

  • baseline period: 65 (54-77) and 38.6%

  • intervention period: 66 (55-77) and 36.7%

Standard of care:

  • baseline period:

68 (58-79) and 36.7%

Intervention period: 68 (57-79) and 36.3%

Intervention: whole body bathing with 2% CHG-impregnated paper towel (PBF Biotech, Taipei, Taiwan) daily or every 2 days

N = 1,501

Comparator: daily wiping bath using commercial cleansing lotion not containing CHG

N = 3,299

Outcomes:

  • incidence of VRE-HAIs (primary)

  • adverse events

Follow-up:

  • mean duration of ICU stay for intervention period: 11.6 days

  • mean duration of ICU stay for control period: 5.5 days

Kengen et al. (2018)12

Australia

Funding source: NR

Study design: single-centre, retrospective, open-label, sequential period, interrupted time series design

Setting: ICU of the Canberra Hospital (31 bed mixed medical and surgical ICU)

Objective: to investigate the effect of implementation of a policy of daily chlorhexidine washing on rates of bloodstream infections, blood culture contamination, newly acquired MDRO isolates and Clostridium difficile infections

Adult ICU patients, excluded if ICU stay was < 24 hours or had an allergy to chlorhexidine

Number of patients:

N = 6,334 in total

Mean age (SD) and % female:

  • 61.1 (17.7) years and 38.4% during control period

  • 62.6 (17.3) years and 37.9% during intervention period

Intervention: daily chlorhexidine washes (2% chlorhexidine-impregnated

washcloths (Teleflex Medical Australia, Sydney, NSW) were to be used according to the supplier’s instructions)

  • Nov 2013-Dec 2015

  • N = 2,970

Comparator: daily washes with water and soap

  • Jan 2011-Aug 2013

  • N = 3,364

Outcomes:

  • 3-monthly counts of clinically significant positive blood cultures attributable to ICU stay (primary)

  • counts of contaminated blood cultures, obtained between 24 hours after ICU admission until ICU discharge

  • newly acquired VRE, MRSA, or multidrug-resistant gram-negative isolates attributable to ICU

  • the incidence rate (counts per 1,000 patient days) of health care facility onset Clostridium difficile infection cases between 48 hours after ICU admission through to 48 hours after ICU discharge

Follow-up:

  • median (IQR) ICU length of stay during control period: 2.58 (1.58–4.85) days

  • median (IQR) ICU length of stay during intervention period: 2.51 (1.62–4.40) days

Garrido-Benedicto et al. (2017)11

Spain

Funding source: NR

Study design: single-centre, prospective, quasi-experimental, non-randomized, single blind, pre-post-design

Setting: medical-surgical intensive care unit in the Hospital Universitari Sant Joan de Reus (12-bed)

Objective: to evaluate the efficacy of daily cleaning with 4% chlorhexidine-impregnated sponges in decreasing contamination of blood cultures in critically-ill patients

Adult ICU patients admitted for > 48 hours; patients with > 20% skin disruption, who were pregnant, or had an allergy to chlorhexidine were excluded

Number of patients:

N = 237

Median age (IQR) and % female:

  • 65.6 (53.9-75.1) years and 43.2% during control period

  • 63.9 (51.6-73.3) years and 39.5% during intervention period

Intervention: body sponges

impregnated with 4% chlorhexidine digluconate (Dis- pomedic sponge C, CV Médica, Tarragona, Spain),

  • 11 months

  • N = 119

Comparator: warm water and CR-32 antiseptic-free dermatological soap (José Collado S.A., Barcelona, Spain)

  • 11 months

  • N = 118

Outcomes:

  • incidence of blood culture contamination

  • incidence of multi-resistant germs

  • adverse effects (i.e., skin alterations)

Follow-up:

  • median (IQR) ICU length of stay during control period: 8 (5-15.25) days

  • median (IQR) ICU length of stay during intervention period: 8 (4-16) days

Ruiz et al. (2017)13

Spain

Funding source: NR

Study design: single-centre, prospective, non-randomized, before-and-after study

Setting: nonsurgical ICU (24 bed) at a university hospital (Hospital La Fe)

Objective: to assess the impact on the nosocomial colonization and infection caused by MDRO by introducing CHG-impregnated wipes into the daily bathing of patients admitted to an ICU

Adult ICU patients

Number of patients:

N = 3,235

Mean age (SD) and % female:

  • 61.4 (15.4) years and 36.9% during control period

  • 61.6 (15.1) years and 37.5% during intervention period

Intervention: CHG wipes (Clinell Wash Cloths; Clinell; Health care, London, UK), impregnated with 2% CHG plus softening agents were introduced for the daily bathing of patients on mechanical ventilation, and for those patients colonized by MDROs

  • Feb 2015-Dec 2015

  • N = 430

Comparator: traditional wash with soap and water for the daily bathing of ICU patients on mechanical ventilation, and for those patients colonized by MDROs

  • Feb 2014-Dec 2014

  • N = NR

Outcomes:

  • monthly trend in number of patients with MDRO acquisition

  • reduction in incidence of colonization by MDROs

  • adverse events (e.g., skin rash)

Follow-up:

  • mean (95% CI) ICU length of stay during control period: 4.1 (3.6-4.6) days

  • mean (95% CI) ICU length of stay during intervention period: 3.9 (3.4-4.5) days

CHG = chlorhexidine gluconate; HAI = hospital-acquired infection; ICU = intensive care unit; IQR = interquartile range; MDRO = multi-drug‒resistant organisms; MRSA = Methicillin-resistant Staphylococcus aureus; NR = not reported; SD = standard deviation; VRE = vancomycin-resistant Enterococcus.

Appendix 3: Critical Appraisal of Included Publications

Note that this appendix has not been copy-edited.

Table 4: Strengths and Limitations of Systematic Reviews and Meta-Analyses Using AMSTAR 26

Strengths

Limitations

Musuuza et al. (2019)9

Review was conducted according to PRISMA and MOOSE guidelines and was registered with PROSPERO (CRD42015032523)

Inclusion criteria included PICO components

Review methods were established a priori

A comprehensive search strategy was used (searched at least 2 databases, provided keywords and/or search strategy, searched the reference lists/bibliographies of included studies)

Study selection was done in triplicate and data extraction was done in duplicate

Included studies were described in adequate detail regarding PICO and study design

Authors used Cochrane Collaboration Tool to assess the risk of bias of the individual studies included in the review

Authors discussed the risk of bias assessment results of individual studies when discussing their results (i.e., conducted subgroup analyses based on RCT or CRT vs. non-randomized studies, bundled vs. non-bundled interventions, CHG wipes vs. CHG solution, and ICU vs. non-ICU settings)

Authors provided adequate explanation for heterogeneity observed in the results of the primary studies through statistical analysis

Authors conducted and discussed graphical and statistical test for publication bias

Authors reported funding sources and potential conflicts of interest for conducting the review

Selection of study designs included in the review was not clearly explained

Authors did not report if trial registries or grey literature was searched. Authors did not provide a list of excluded studies with reasons for exclusion

Authors did not report on the sources of funding or conflicts of interest for the included studies

Huang et al. (2016)8

Review was conducted according to PRISMA guidelines and was registered with PROSPERO (CRD42014014973)

Inclusion criteria included PICO components

Review methods were established a priori

A comprehensive search strategy was used (searched at least 2 databases, provided keywords and/or search strategy, searched the reference lists/bibliographies of included studies)

Data were extracted from included studies in duplicate

Included studies were described in adequate detail regarding PICO and study design

Authors used Cochrane Risk of Bias tool to assess the risk of bias for RCTs and the Newcastle-Ottawa Quality Assessment Scale to assess the quality of non-randomized studies included in the review

Authors discussed the RoB assessment results of individual studies when discussing their results

Authors provided adequate explanation for heterogeneity observed in the results of the primary studies through statistical analysis

Selection of study designs included in the review was not clearly explained

Authors did not report if trial registries or grey literature was searched

Authors did not report whether study selection was done in duplicate

Authors did not provide a list of excluded studies with reasons for exclusion

Authors did not report on the sources of funding or conflicts of interest for the included studies

Authors did not adequately investigate the impact of publication bias on the results of the SR

Authors did not report the funding source or potential conflicts of interest for the authors conducting the review

Discrepancies were noted in the reporting of study characteristics for studies that overlapped with Musuuza et al. (2019),9 which leads to uncertainty about other aspects of reporting for this study

AMSTAR 2 = A MeaSurement Tool to Assess systematic Reviews 2; MOOSE = Meta-analyses Of Observational Studies in Epidemiology; PICO = population, intervention, comparator, outcome; PRISMA = Preferred Reporting Items for Systematic Reviews and Meta-analyses; RCT = randomized controlled trial; RoB = risk of bias; SR = systematic review.

Table 5: Strengths and Limitations of Clinical Studies Using the Downs and Black Checklist7

Strengths

Limitations

Randomized controlled trial

Kapadia et al. (2016)10

Study objective was clearly described

Outcomes to be measured were clearly described, and were valid and reliable

Inclusion/exclusion criteria and participant characteristics were clearly described

Intervention and comparator were clearly described

Randomization procedures were clearly reported

Sample size calculation was reported

Data analyses were planned a priori

Main findings were clearly described

Estimates of random variability for the main outcomes were clearly described

All important adverse events were reported

Actual probability values were reported for the main outcomes

Statistical tests used to assess the main outcomes were appropriate with sufficient statistical power to detect a difference

Characteristics of participants who were randomized but did not complete the study were not described and the numbers of non-participants differed between study groups (N = 35 in intervention group, N = 8 in control group)

Study was conducted in US at a single tertiary care centre; thus, findings may not be generalizable to Canada or to other centres

Study authors acknowledged in their discussion that some study participants may not have reliably followed directions for the intervention they were assigned; however, no data were reported to support this

Per-protocol analysis was conducted instead of intention-to-treat; thus, increasing the risk of imbalanced patient characteristics between study arms

Authors reported that the study was double-blinded in the Discussion, but no details provided in the Methods

Non-randomized studies

Tien et al. (2021)14

Study objective was clearly described

Outcomes to be measured were clearly described, and were valid and reliable

Inclusion/exclusion criteria and participant characteristics were clearly described

Intervention and comparator were clearly described

Data analyses were planned a priori

Main findings were clearly described

Statistical tests used to assess the main outcomes were appropriate

All-important adverse events were reported

Non-randomized, the 4 ICUs with a higher baseline VRE-HAIs incidence were assigned to provide 2% CHG bathing on a daily (or every 2 days) basis to all patients (CHG group), while the 4 ICUs with a lower baseline VRE-HAIs incidence were assigned to provide standard care (without 2% CHG bathing) to all patients (standard care group)

Study was conducted in Taiwan in a single hospital across 8 ICUs; thus, findings may not be generalizable to Canada or to other centres

Authors did not discuss statistical power

Kengen et al. (2018)12

Study objective was clearly described

Outcomes to be measured were clearly described, and were valid and reliable

Inclusion and exclusion criteria and participant characteristics were clearly described

Intervention and comparator were clearly described

Data analyses were planned a priori

Main findings were clearly described

Actual probability values were reported for the main outcomes

Estimates of random variability for the main outcomes were clearly described

Retrospective, non-randomized

Study was conducted in Australia in a single hospital ICU; thus, findings may not be generalizable to Canada or to other centres

Potentially insufficient statistical power to detect changes in infection and colonization rates

No measure of nursing staff compliance in administration of study intervention

Potential for unmeasured confounding

Garrido-Benedicto et al. (2017)11

Study objective was clearly described

Outcomes to be measured were clearly described, and were valid and reliable

Inclusion and exclusion criteria and participant characteristics were clearly described

Intervention and comparator were clearly described

Data analyses were planned a priori

Main findings were clearly described

Estimates of random variability for the main outcomes were clearly described

Statistical tests used to assess the main outcomes were appropriate with sufficient statistical power to detect a difference

All-important adverse events were reported

Non-randomized

Actual probability values were not reported for the main outcomes

Study was conducted in Spain in a single hospital ICU; thus, findings may not be generalizable to Canada or to other centres

Ruiz et al. (2017)13

Study objective was clearly described

Outcomes to be measured were clearly described

Inclusion/exclusion criteria and participant characteristics were clearly described

Intervention and comparator were clearly described

Data analyses were planned a priori

Main findings were clearly described

Statistical tests used to assess the main outcomes were appropriate

All-important adverse events were reported

Non-randomized

Study was conducted in Spain in a single hospital ICU; thus, findings may not be generalizable to Canada or to other centres

Only patients who required mechanical ventilation or were colonized with multi-drug‒resistant organism(s) were subject to the intervention of CHG bathing while in ICU, rather than entire ICU population as a means to control spread of MDROs

Actual probability values were not reported for the main outcomes

Authors did not discuss statistical power

CHG = chlorhexidine gluconate; ICU = intensive care unit; MDRO = multi-drug‒resistant organisms.

Appendix 4: Main Study Findings and Authors’ Conclusions

Note that this appendix has not been copy-edited.

Summary of Findings Included Systematic Reviews and Meta-Analyses

Musuuza et al. (2019)9

Main Study Findings

SR and meta-analysis of RCTs, cluster randomized trials and quasi-experimental studies to examine the effect of CHG bathing on prevention of HABSIs and assessed fidelity to implementation of this behavioural intervention in adult health care settings.

Relevant primary studies: The SR included 26 studies (8 RCTs and 18 non-randomized studies) that measured the clinical effectiveness of CHG bathing on prevention of hospital-acquired bloodstream infection (HABSIs); however, only primary studies that compared bathing with CHG wipes versus soap and water in critical care settings were relevant to this report (2 RCTs and 7 non-randomized studies). Although the SR included meta-analyses, there was no meta-analysis specific to the primary studies relevant to the current report. Therefore, relevant results were summarized individually by primary study.

Summary of relevant findings from the systematic review:

Author’s Conclusion

“We found that CHG bathing of patients is associated with a consistent, clinically important, and statistically significant reduction in the risk of HABSIs. This effect was consistent across study settings, study designs, whether the intervention was bundled or not, and whether a no-rinse approach (i.e., CHG-impregnated wipes) or CHG solution requiring rinsing was used.” (p.6)

Huang et al. (2016)8

Main Study Findings

SR and meta-analysis of RCTs, cluster randomized trials and quasi-experimental studies to determine whether daily CHG bathing significantly decreases the rates of HAIs in adult ICUs.

Relevant primary studies: The SR included 15 studies (3 RCTs and 12 non-randomized studies) that measured the clinical effectiveness of CHG bathing on prevention of HAIs; however, only primary studies that compared bathing with CHG wipes versus soap and water in critical care settings were relevant to this report (1 RCTs and 6 non-randomized studies). Although the SR included meta-analyses, there was no meta-analysis specific to the primary studies relevant to the current report. Therefore, relevant results were summarized individually by primary study. Results that overlap with those reported by Musuuza and colleagues9 are not repeated here (see Appendix 5 for overlap).

Summary of relevant findings from the systematic review:

Author’s Conclusion

“This further meta-analysis demonstrated that daily CHG bathing had an overwhelming effect on decreasing the rates of the composite primary outcomes, including CRBSI, CAUTI, VAP, and acquisition of MRSA and VRE.” (p.1166)

Summary of Findings of Included Primary Clinical Studies

Randomized Controlled Trial — Main Study Findings

Kapadia et al. (2016)10

Periprosthetic infections, n (%)

Deep periprosthetic infections, n (%)

Superficial periprosthetic infections, n (%)

Adverse events

Author’s Conclusion

“In this study, chlorhexidine gluconate-impregnated cloths the night before and morning of admission significantly decreased periprosthetic infections in TJA [total joint arthroplasty] patients when compared to standard antiseptic bathing overall (OR 8.15).” (p.2859)

Non-Randomized Studies — Main Study Findings

Tien et al. (2021)14

CHG bathing

Standard of care

Adverse effects

Author’s Conclusion

“This is the first study to examine the effect of daily 2% CHG bathing on VRE-HAIs incidence at ICUs, in the context of active VRE surveillance. Our results show that 2% CHG bathing was independently associated with a 70% lower risk of VRE-HAIs. In contrast, standard care during the same period had no effect on the incidence of VRE-HAIs. This provides a strong evidence that the observed decrease in VRE-HAIs in the CHG group is the effect of 2% CHG bathing, rather than the effect of advances in standard care during the same period.” (p.1017)

“In conclusion, CHG bathing is a simple, safe, and highly effective approach to prevent VRE-HAIs at ICUs, in the context of active VRE surveillance with contact isolation. Further investigations on using CHG bathing to prevent VRE-HAIs in non-ICUs settings are warranted.” (p.1020)

Kengen et al. (2018)12

Main Study Findings

Blood culture contamination in ICU

New acquisition of multi-drug–resistant organisms (MDROs) in the ICU

a Adjusted for: patient age, sex, Acute Physiology and Chronic Health Evaluation (APACHE) III score, mechanical ventilation, intensive care unit and hospital length of stay, comorbid conditions, admission source, and the monthly prevalence of hospital-wide positive cultures.

Author’s Conclusion

“In this single-centre, retrospective, open-label, sequential period, ITS analysis, implementation of a unit-level policy of once daily washing with chlorhexidine, compared with water and soap, was not associated with a reduction in the number of clinically significant blood cultures, blood culture contamination, or ICU-associated new acquisition of MDRO.” (p.236)

Garrido-Benedicto et al. (2017)11

Main Study Findings

Blood culture contamination, n (%)

Adverse events:

Author’s Conclusion

“The use of 4% chlorhexidine soap in the daily washing of critical patients reduces the incidence of blood culture contamination, and its effect lasts over time. A low rate of blood culture contamination is a quality of care marker. It gives rise to cost savings due to the use of diagnostic tests and unnecessary treatments, as well as aiding the clinical management of patients.” (p.103)

Ruiz et al. (2017)13

Main Study Findings

Colonization by MDROs

Pre-intervention period:

Intervention period:

Pre-intervention period versus intervention period:

Infections caused by MDROs

Adverse events

Author’s Conclusion

“Our study demonstrates the association between daily bathing of the critical patient with CHG-impregnated wipes and the reduction of MDRO colonization, even in an endemic situation caused by multidrug-resistant gram-negative bacteria.” (p.1071)

“In conclusion, the use of CHG-impregnated wipes is an effective tool in the reduction of cross-transmission by MDROs, and therefore on the colonization rate by MDROs, even in an endemic situation because of multidrug-resistant gram-negative bacteria. It is possible that the inefficiency of standard measures for the control of MDRO transmission could be because of high inoculum (colonization pressure of 29.6%), and that the use of CHG could have helped control the situation by means of the reduction of this inoculum.” (p.1073)

Appendix 5: Overlap Between Included Systematic Reviews

Note that this appendix has not been copy-edited.

Table 6: Overlap in Relevant Primary Studies Between Included Systematic Reviews

Primary study citation

Huang (2016)8

Musuuza (2019)9

Bleasdale et al. Arch Intern Med. 2007;167(19):2073–9.

Yes

Yes

Boonyasiri et al. Infect Control Hosp Epidemiol. 2016;37(3):245–53.

No

Yes

Cassir et al. Eur J Clin Microbiol Infect Dis. 2015;34(5):999–1004.

Yes

Yes

Dixon and Carver. Am J Infect Control. 2010;38(10):817–21.

Yes

Yes

Duszyńska et al. Anaesthesiol Intensive Ther. 2017;49(1):28–33.

No

Yes

Holder and Zellinger. J Clin Outcomes Manag. 2009;16(11):509–13.

Yes

Yes

Kassakian et al. Infect Control Hosp Epidemiol. 2011;32(3):238–43.

No

Yes

Popovich et al. Infect Control Hosp Epidemiol. 2009;30(10):959–63.

Yes

Yes

Popovich et al. Intensive Care Med. 2010;36(5):854–8.

Yes

Yes

Vernon et al. Arch Intern Med 2006;166:306-312.

Yes

No

Appendix 6: References of Potential Interest

Note that this appendix has not been copy-edited.

Previous CADTH Reports

CADTH. 2020. Antisepsis for Urinary Catheter Insertion: A Review of Clinical Effectiveness and Guidelines. https://www.cadth.ca/antisepsis-urinary-catheter-insertion-review-clinical-effectiveness-and-guidelines

CADTH 2019. Chlorhexidine Gluconate for Skin Preparation during Minor Procedures: Clinical Effectiveness and Guidelines https://www.cadth.ca/chlorhexidine-gluconate-skin-preparation-during-minor-procedures-clinical-effectiveness-and

CADTH 2016. Chlorhexidine Gluconate Wipes for Infection Prevention in Acute and Critical Care: A Review of Clinical Effectiveness and Cost-Effectiveness https://www.cadth.ca/chlorhexidine-gluconate-wipes-infection-prevention-acute-and-critical-care-review-clinical